409 related articles for article (PubMed ID: 28409322)
1. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.
Aparicio LMA; Fernandez IP; Cassinello J
Clin Transl Oncol; 2017 Oct; 19(10):1175-1182. PubMed ID: 28409322
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
3. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor.
Santoni M; Berardi R; Amantini C; Burattini L; Santini D; Santoni G; Cascinu S
Int J Cancer; 2014 Jun; 134(12):2772-7. PubMed ID: 24114790
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma.
Bianchi L; Rossi L; Tomao F; Papa A; Zoratto F; Tomao S
Endocr Relat Cancer; 2013 Oct; 20(5):R233-45. PubMed ID: 23833016
[TBL] [Abstract][Full Text] [Related]
5. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients.
Rinchai D; Verzoni E; Huber V; Cova A; Squarcina P; De Cecco L; de Braud F; Ratta R; Dugo M; Lalli L; Vallacchi V; Rodolfo M; Roelands J; Castelli C; Chaussabel D; Procopio G; Bedognetti D; Rivoltini L
Clin Transl Med; 2021 Jun; 11(6):e434. PubMed ID: 34185403
[TBL] [Abstract][Full Text] [Related]
6. Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Hara T; Miyake H; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):363-369. PubMed ID: 28169111
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Catalano M; Procopio G; Sepe P; Santoni M; Sessa F; Villari D; Nesi G; Roviello G
Pharmacol Ther; 2023 Sep; 249():108499. PubMed ID: 37479037
[TBL] [Abstract][Full Text] [Related]
8. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms.
Buczek M; Escudier B; Bartnik E; Szczylik C; Czarnecka A
Biochim Biophys Acta; 2014 Jan; 1845(1):31-41. PubMed ID: 24135488
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.
Schöffski P; Dumez H; Clement P; Hoeben A; Prenen H; Wolter P; Joniau S; Roskams T; Van Poppel H
Ann Oncol; 2006 Aug; 17(8):1185-96. PubMed ID: 16418310
[TBL] [Abstract][Full Text] [Related]
10. Kinase inhibitors in the treatment of renal cell carcinoma.
Larkin JM; Eisen T
Crit Rev Oncol Hematol; 2006 Dec; 60(3):216-26. PubMed ID: 16860997
[TBL] [Abstract][Full Text] [Related]
11. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy in metastatic renal cell cancer.
Ravaud A; Gross-Goupil M; Bellmunt J
Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
[TBL] [Abstract][Full Text] [Related]
13. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Miyake H; Imai S; Harada K; Fujisawa M
Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
[TBL] [Abstract][Full Text] [Related]
14. SOX9 was involved in TKIs resistance in renal cell carcinoma via Raf/MEK/ERK signaling pathway.
Li XL; Chen XQ; Zhang MN; Chen N; Nie L; Xu M; Gong J; Shen PF; Su ZZ; Weng X; Tan JY; Zhao T; Zeng H; Zhou Q
Int J Clin Exp Pathol; 2015; 8(4):3871-81. PubMed ID: 26097571
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib in renal cell carcinoma.
Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
[TBL] [Abstract][Full Text] [Related]
16. Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients.
Semeniuk-Wojtaś A; Lubas A; Stec R; Szczylik C; Niemczyk S
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941701
[TBL] [Abstract][Full Text] [Related]
17. Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
Gao X; McDermott DF
Cancer J; 2018; 24(4):171-179. PubMed ID: 30119080
[TBL] [Abstract][Full Text] [Related]
18. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
[TBL] [Abstract][Full Text] [Related]
19. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
20. Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors.
Esther J; Hale P; Hahn AW; Agarwal N; Maughan BL
Drugs Aging; 2019 May; 36(5):395-401. PubMed ID: 30784023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
